ABEO — Abeona Therapeutics Share Price
Last Trade - 00:00- $118.44m
- $42.63m
- $10.00m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.89 | 0.84 | 3 | n/a | 10 | 0.5 | 1.43 | 57.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Directors
- Steven Rouhandeh CHM (64)
- Michael Amoroso PRE (43)
- Vishwas Seshadri
- Edward Carr CAO (51)
- Christine Silverstein DRC (38)
- Leila Alland (58)
- Mark Alvino IND (53)
- Faith Charles (59)
- Paul Mann (45)
- Todd Wider (56)
- Donald Wuchterl
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- June 22nd, 1989
- Public Since
- September 19th, 1980
- No. of Shareholders
- 170
- No. of Employees
- 76
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 101,227,014
- Address
- 1330 Avenue of the Americas Fl 33, NEW YORK, 10019-5442
- Web
- https://abeonatherapeutics.com/
- Phone
- +1 6468134701
- Auditors
- Whitley Penn LLP
Latest News for ABEO
Upcoming events for ABEO
Q3 2021 Abeona Therapeutics Inc Earnings Release
Similar to ABEO
ACASTI PHARMA CL A ORD
NASDAQ Capital Market
ACHIEVE LIFE SCIENCES ORD
NASDAQ Capital Market
ACURX PHARMACEUTICALS ORD
NASDAQ Capital Market
ADDEX THERAPEUTICS ADR
NASDAQ Capital Market
ADVAXIS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:54 UTC, shares in Abeona Therapeutics are trading at $1.17. This share price information is delayed by 15 minutes.
Shares in Abeona Therapeutics last closed at $1.17 and the price had moved by -59.38% over the past 365 days. In terms of relative price strength the Abeona Therapeutics share price has underperformed the S&P500 Index by -69.18% over the past year.
The overall consensus recommendation for Abeona Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Abeona Therapeutics does not currently pay a dividend.
Abeona Therapeutics does not currently pay a dividend.
Abeona Therapeutics does not currently pay a dividend.
To buy shares in Abeona Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.17, shares in Abeona Therapeutics had a market capitalisation of $118.44m.
Here are the trading details for Abeona Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ABEO
Based on an overall assessment of its quality, value and momentum Abeona Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abeona Therapeutics is $5.00. That is 327.35% above the last closing price of $1.17.
Analysts covering Abeona Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.65 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abeona Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -58.41%.
As of the last closing price of $1.17, shares in Abeona Therapeutics were trading -31.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Abeona Therapeutics.
Abeona Therapeutics' management team is headed by:
- Steven Rouhandeh - CHM
- Michael Amoroso - PRE
- Vishwas Seshadri -
- Edward Carr - CAO
- Christine Silverstein - DRC
- Leila Alland -
- Mark Alvino - IND
- Faith Charles -
- Paul Mann -
- Todd Wider -
- Donald Wuchterl -
We do not have data on Abeona Therapeutics' shareholders